Indaptus Therapeutics Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
FY EPS (est.)
-$1.72next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Earnings Release (Form 10-Q) | 13 Nov 2026 |
Monitoring Framework
Key Performance Indicators
Cash and Cash Equivalents Quarterly1.5MTarget: Sufficient capital to fund operations and resume clinical development
Quarterly Net Loss Quarterly-2.5MTarget: Reduction in cash burn rate through strategic cost management
Watch Items
- Capital Raising and Financing ActivitiesTrigger: Dwindling cash reserves of $1.5 million as of March 31, 2026Action: Secure additional equity or debt financing to extend the operational runway
- Clinical Development Strategy and Trial ResumptionTrigger: Halted or paused clinical trials following change of controlAction: Evaluate development programs and announce updated clinical timelines under new management
- Board and Executive Leadership StabilityTrigger: Resignation of directors David E. Lazar and Avraham Ben-Tzvi effective June 5, 2026Action: Monitor board composition and alignment with major shareholders
Research as of 20 Jun 2026